Takeda Pharmaceutical Company Limited Logo

Takeda Pharmaceutical Company Limited

R&D-driven biopharma creating medicines for Oncology, Rare Diseases, GI, and Neuroscience.

4502 | T

Overview

Corporate Details

ISIN(s):
JP3463000004
LEI:
Country:
Japan
Address:
大阪市中央区道修町四丁目1番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Takeda Pharmaceutical Company Limited is a global, R&D-driven biopharmaceutical leader dedicated to discovering and delivering life-transforming treatments. With a history spanning over 240 years, the company translates science into highly innovative medicines. Its core business activities include the research, development, manufacturing, and commercialization of pharmaceutical drugs. Takeda focuses its efforts on four core therapeutic areas: Oncology, Rare Diseases, Gastroenterology, and Neuroscience, with additional targeted investments in Plasma-Derived Therapies and Vaccines. The company is committed to a patient-centered approach, aiming to create better health and a brighter future for people worldwide through its diverse and balanced portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-30 07:48
Interim Report
確認書
Japanese 9.4 KB
2025-10-30 07:47
Interim Report
半期報告書-第149期(2025/04/01-2026/03/31)
Japanese 483.8 KB
2025-10-30 07:43
Earnings Release
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consol…
English 22.5 KB
2025-07-01 05:11
Registration Form
訂正発行登録書
Japanese 11.9 KB
2025-07-01 05:11
Registration Form
訂正発行登録書
Japanese 11.3 KB
2025-07-01 05:11
Post-Annual General Meeting Information
臨時報告書
Japanese 28.6 KB
2025-06-25 09:33
Registration Form
確認書
Japanese 9.4 KB
2025-06-25 09:32
Governance Information
内部統制報告書-第148期(2024/04/01-2025/03/31)
Japanese 26.8 KB
2025-06-25 09:31
Annual Report
有価証券報告書-第148期(2024/04/01-2025/03/31)
Japanese 3.6 MB
2025-06-12 04:51
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.0 KB
2025-06-10 08:31
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 65.6 KB
2025-06-06 03:43
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 129.2 KB
2025-06-02 08:34
Registration Form
発行登録書(株券、社債券等)
Japanese 50.3 KB
2025-05-14 05:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 31.7 KB
2025-04-14 04:57
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.5 KB

Automate Your Workflow. Get a real-time feed of all Takeda Pharmaceutical Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Takeda Pharmaceutical Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Takeda Pharmaceutical Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
ARGENX SE Logo
Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.
United States of America ARGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.